You are here

Article info

Article menu
Original article
Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
Free

Authors

  1. Correspondence to Dr Morgane Beck, OMEDIT Alsace, Agence Régionale de Santé, 14, rue du Maréchal Juin, Strasbourg 67084, France; Morgane.BECK{at}ars.sante.fr
View Full Text

Citation

Beck M, Michel B, Rybarczyk-Vigouret M, et al
Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
European Journal of Hospital Pharmacy 2017;24:85-90.

Publication history

  • Received January 29, 2016
  • Revised March 3, 2016
  • Accepted March 7, 2016
  • First published March 24, 2016.
Online issue publication 
May 01, 2020

Article Versions

  • Abstract in French

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/